EZH2 inhibition enhances the activity of Carboplatin in aggressive-variant prostate cancer cell lines.
Latarani M, Pucci P, Eccleston M, Manzo M, Gangadharannambiar P, Fischetti I, Alborelli I, Mongiardini V, Mahmood N, Colombo MP, Grimaldi B, Rigas S, Akamatsu S, Hawkes C, Wang Y, Jachetti E, Crea F.
Latarani M, et al. Among authors: akamatsu s.
Epigenomics. 2025 Jan 29:1-10. doi: 10.1080/17501911.2025.2453419. Online ahead of print.
Epigenomics. 2025.
PMID: 39878501
Free article.